February 2026 in “Journal of Dermatological Treatment” This research describes CG2001's promising safety profile and reduced systemic exposure as an alternative to finasteride, supporting its further development for androgenic alopecia treatment in future trials.
This study found that the novel alcohol-free topical foam CG2001, combining minoxidil and finasteride, was safe and well-tolerated in Chinese males with androgenetic alopecia, with significantly lower systemic exposure to finasteride compared to oral administration, potentially reducing sexual side effects.
In this phase I study, CG2001, a topical foam combining minoxidil and finasteride, was found to be safe and well-tolerated in Chinese males with androgenetic alopecia, showing significantly reduced systemic finasteride exposure compared to oral administration, potentially reducing related side effects.